Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trifluridine
- Development stage
- Approved
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic, Oral
01
Overview
Trifluridine is a fluorinated pyrimidine nucleoside analog and nucleoside metabolic inhibitor. It acts as an antiviral agent, primarily used in ophthalmic solutions for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis caused by herpes simplex virus types 1 and 2. Mechanistically, trifluridine inhibits viral DNA synthesis by incorporating into viral DNA in place of thymidine, thereby disrupting DNA replication. In addition to its antiviral use, trifluridine is also a component of the oral combination chemotherapy drug Lonsurf (trifluridine/tipiracil), where it serves as an antimetabolite that interferes with cancer cell proliferation by incorporation into tumor cell DNA[1][3][4][9].
- Brand names
- Viroptic
- Other names
- 5-(Trifluoromethyl)deoxyuridine5-Trifluoromethyl-2-deoxyuridineTrifluoromethyldeoxyuridineTrifluorothymidineTrifluorothymine deoxyribosideTrifluridinTrifluridinaTrifluridinum
02
Targets
HSV DNA pol (Herpes simplex virus DNA polymerase)
Beyond the preview
Go deeper on trifluridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trifluridine.